Safety of topical corticosteroids in pregnancy

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Chi, Ching Chi ^a,b   Wang, Shu Hui ^c   Wojnarowska, Fenella ^d   Kirtschig, Gudula ^e   Davies, Emily ^f   Bennett, Cathy ^g  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f AMERSHAM HOSPITAL   (United Kingdom)

^g Institute for Clean Growth and Future Mobility   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DERMATOLOGICAL AGENT;

APGAR SCORE; CESAREAN SECTION; CLEFT LIP; CLEFT LIP FACE PALATE; CLEFT PALATE; CONGENITAL DISORDER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FETUS DEATH; HUMAN; HYPOSPADIAS; INSTRUMENTAL DELIVERY; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; MATERNAL EXPOSURE; META ANALYSIS; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ABNORMALITIES, DRUG-INDUCED; BIRTH WEIGHT; CASE CONTROL STUDY; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG EFFECTS; FEMALE; OBSERVATIONAL STUDY; PREGNANCY COMPLICATIONS; PREMATURITY; SKIN PIGMENTATION; TOPICAL DRUG ADMINISTRATION;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; BIRTH WEIGHT; CASE-CONTROL STUDIES; CLEFT LIP; CLEFT PALATE; COHORT STUDIES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFANT, LOW BIRTH WEIGHT; OBSERVATIONAL STUDIES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; SKIN PIGMENTATION;

EID: 84962935550     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007346.pub3     Document Type: Review

References (80)

1. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ. Maternal corticosteroid use and orofacial clefts. American Journal of Obstetrics & Gynecology 2007;197(6):585.e1-585.e7. [MEDLINE: 18060943]
2. Carmichael SL, Ma C, Werler MM, Olney RS, Shaw GM, National Birth Defects Prevention Study. Maternal corticosteroid use and hypospadias. Journal of Pediatrics 2009;155(1):39-44. [MEDLINE: 19394038]
3. Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corticosteroids in pregnancy: a population-based cohort study. Journal of Investigative Dermatology 2011;131(4):884-91. [MEDLINE: 21191410]
4. Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatology 2013;149(11):1274-80. [MEDLINE: 24005903]
5. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56(5):335-40. [MEDLINE: 9451758]
6. Edwards MJ, Agho K, Attia J, Diaz P, Hayes T, Illingworth A, et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. American Journal of Medical Genetics Part A 2003;120A(4):459-63. [MEDLINE: 12884422]
7. Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Canadian Medical Association Journal 2011;183(7):796-804. [MEDLINE: 21482652]
8. Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate-Craniofacial Journal 2003;40(6):624-8. [MEDLINE: 14577813]
9. Mahé A, Perret JL, Ly F, Fall F, Rault JP, Dumont A. The cosmetic use of skin-lightening products during pregnancy in Dakar, Senegal: a common and potentially hazardous practice. Transactions of the Royal Society of Tropical Medicine & Hygiene 2007;101(2):183-7. [MEDLINE: 17023012]
10. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstetricia et Gynecologica Scandinavica 2002;81(3):234-9. [MEDLINE: 11966480]
11. Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P, et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Research 2003;67(12):968-70. [MEDLINE: 14745915]
12. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Research 2014;100(6):499-506. [MEDLINE: 24777675]
13. Skuladottir H, Wilcox A, McConnaughey R, Vindenes H, Lie RT. First-trimester nonsystemic corticosteroid use and the risk of oral clefts in Norway. Annals of Epidemiology 2014;24(9):635-40. [PUBMED: 25127739]
14. Skuladottir H, Wilcox A, McConnaughey R, Vindenes H, Lie RT. First-trimester nonsystemic corticosteroid use and the risk of oral clefts in Norway. Annals of Epidemiology 2014;24(9):635-40. [PUBMED: 25127739]
15. Bjørn AM, Nielsen RB, Norgaard M, Nohr EA, Ehrenstein V. Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study. Clinical Epidemiology 2013;5(1):287-94. [MEDLINE: 23983489]
16. Bjørn AM, Ehrenstein V, Hundborg HH, Nohr EA, Sørensen HT, Nørgaard M. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. American Journal of Therapeutics 2014;21(2):73-80. [MEDLINE: 23011170]
17. Lin Y, Shu S, Tang S. A case-control study of environmental exposures for nonsyndromic cleft of the lip and/or palate in eastern Guangdong, China. International Journal of Pediatric Otorhinolaryngology 2014;78(3):544-50. [MEDLINE: 24485177]
18. Zandi M, Heidari A. An epidemiologic study of orofacial clefts in Hamedan City, Iran: a 15-year study. Cleft Palate-Craniofacial Journal 2011;48(4):483-9. [MEDLINE: 20572780]
19. Altman DG. Practical Statistics for Medical Research. 1st Edition. London: Chapman & Hall, 1991.
20. Ambros-Rudolph CM. Dermatoses of pregnancy [Schwangerschaftsdermatosen]. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology] 2006;4(9):748-61. [MEDLINE: 16928244;: doi:10.1111/j.1610-0387.2006.06008.x]
21. Anderson GG, Rotchell Y, Kaiser DG. Placental transfer of methylprednisolone following maternal intravenous administration. American Journal of Obstetrics & Gynecology 1981;140(6):699-701. [MEDLINE: 7020419]
22. Arosarena OA. Cleft lip and palate. Otolaryngologic Clinics of North America 2007;40(1):27-60. [MEDLINE: 17346560]
23. Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. Journal of Clinical Investigation 1975;56(6):1548-54. [MEDLINE: 1202085]
24. Ballard PD, Hearney EF, Smith MB. Comparative teratogenicity of selected glucocorticoids applied ocularly in mice. Teratology 1977;16(2):175-80. [MEDLINE: 929433]
25. Baumann L, Kerdel F. Topical glucocorticoids. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al. editor(s). Fitzpatrick's Dermatology in General Medicine. 5th Edition. New York: McGraw-Hill, 1999:2713-7.
26. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. Journal of Pediatrics 1972;81(5):936-45. [MEDLINE: 5086721]
27. Berth-Jones J. Chapter 75. Topical therapy. In: Burns T, Breathnach SM, Cox N, Griffiths C editor(s). Rook's Textbook of Dermatology. 7th Edition. Oxford: Blackwell Publishing, 2004:1-52.
28. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. Drugs in Pregnancy and Lactation. 8th Edition. Philadelphia: Lippincott Williams & Wilkins, 2008.
29. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. American Journal of Medical Genetics 1999;86(3):242-4. [MEDLINE: 10482873]
30. Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. New England Journal of Medicine 2001;344(7):467-71. [MEDLINE: 11172187]
31. Chi CC, Kirtschig G, Aberer W, Gabbud JP, Lipozenčić J, Kárpáti S, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. British Journal of Dermatology 2011;165(5):943-52. [MEDLINE: 21729030]
32. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC III, Wenstrom KD. Williams Obstetrics. 22nd Edition. New York: McGraw-Hill, 2005.
33. Czeizel AE. Birth defects are preventable. International Journal of Medical Sciences 2005;2(3):91-2. [MEDLINE: 16007259]
34. Devane D, Begley CM, Clarke M, Horey D, O'Boyle C. Evaluating maternity care: A core set of outcome measures. Birth 2007;34(2):164-172. [MEDLINE: 17542821]
35. Gitau R, Cameron A, Fisk NM, Glover V. Fetal exposure to maternal cortisol. The Lancet 1998;352(9129):707-8. [MEDLINE: 9728994]
36. Gitau R, Fisk NM, Teixeira JM, Cameron A, Glover V. Fetal hypothalamic-pituitary-adrenal stress responses to invasive procedures are independent of maternal responses. Journal of Clinical Endocrinology & Metabolism 2001;86(1):104-9. [MEDLINE: 11231985]
37. GlaxoSmithKline. Cutivate cream prescribing information. Pharmaceutical Information 2002.
38. Schünemann H, Brozek J, Guyatt G, Oxman A (editors). GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. [updated October 2013] The GRADE Working Group, 2013. Available from www.guidelinedevelopment.org/handbook.
39. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reproductive Toxicology 2004;18(1):93-101. [MEDLINE: 15013068]
40. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction -GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
41. Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. International Journal of Dermatology 2002;41(4):197-203. [MEDLINE: 12031026]
42. Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81, 975 mothers from the UK General Practice Research Database. Pharmacoepidemiology & Drug Safety 2006;15(8):555-64. [MEDLINE: 16767799]
43. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology 2006;54(1):1-18. [MEDLINE: 16384751]
44. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
45. Ikegami M, Jobe AH, Newnham J, Polk DH, Willet KE, Sly P. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs. American Journal of Respiratory & Critical Care Medicine 1997;156(1):178-84. [MEDLINE: 9230744]
46. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD002954]
47. Katz VL, Thorp JM Jr, Bowes WA Jr. Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone. American Journal of Obstetrics & Gynecology 1990;162(2):396-7. [MEDLINE: 2309822]
48. Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D. Interventions for bullous pemphigoid. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002292.pub2]
49. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatologic Clinics 2006;24(2):167-97. [MEDLINE: 16677965]
50. Marsland AM, Chalmers RJG, Hollis S, Leonardi-Bee J, Griffiths CEM. Interventions for chronic palmoplantar pustulosis. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD001433.pub2]
51. Meadows M. Pregnancy and the drug dilemma. FDA Consumer 2001;35(3):16-20. [MEDLINE: 11458544]
52. Mehta DK. British National Formulary. British National Formulary. 2nd Edition. BMJ Publishing Group Ltd and RPS Publishing, 2006:BMJ Publishing Group Ltd and RPS Publishing 2006.
53. Murphy BE, Clark SJ, Donald IR, Pinsky M, Vedady D. Conversion of maternal cortisol to cortisone during placental transfer to the human fetus. American Journal of Obstetrics & Gynecology 1974;118(4):538-41. [MEDLINE: 4812574]
54. Murphy VE, Fittock RJ, Zarzycki PK, Delahunty MM, Smith R, Clifton VL. Metabolism of synthetic steroids by the human placenta. Placenta 2007;28(1):39-46. [MEDLINE: 16549198]
55. Nanda R, Van der Linden FP, Jansen HW. Production of cleft palate with dexamethasone and hypervitaminosis A in rat embryos. Experientia 1970;26(10):1111-2. [MEDLINE: 4320730]
56. Narama I. Reproduction studies of diflorasone diacetate (DDA) 4. Teratogenicity study in rabbits by percutaneous administration. Pharmacometrics 1984;28(2):241-50.
57. Nasjleti CE, Avery JK, Spencer HH, Walden JM. Tritiated cortisone distribution and induced cleft palate in mice. Journal of Oral Therapeutics & Pharmacology 1967;4(1):71-82. [MEDLINE: 6053766]
58. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62(6):385-92. [MEDLINE: 11091360]
59. Petersen MC, Nation RL, Ashley JJ, McBride WG. The placental transfer of betamethasone. European Journal of Clinical Pharmacology 1980;18(3):245-7. [MEDLINE: 7439243]
60. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
61. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998;58(1):2-5. [MEDLINE: 9699238]
62. Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR): epidemiology and etiology. Pediatric Endocrinology Reviews 2009;6(Suppl 3):332-6. [MEDLINE: 19404231]
63. Schering. ELOCON cream prescribing information. Pharmaceutical Information 2003.
64. Shah RM, Kilistoff A. Cleft palate induction in hamster fetuses by glucocorticoid hormones and their synthetic analogues. Journal of Embryology & Experimental Morphology 1976;36(1):101-8. [MEDLINE: 978122]
65. Sifton DW. Physicians' Desk Reference. 6th Edition. Montvale: Medical Economics Company, 2002.
66. Smith MA, Thomford PJ, Mattison DR, Slikker W Jr. Transport and metabolism of dexamethasone in the dually perfused human placenta. Reproductive Toxicology 1988;2(1):37-43. [MEDLINE: 2980400]
67. Stanier P, Moore GE. Genetics of cleft lip and palate: syndromic genes contribute to the incidence of non-syndromic clefts. Human Molecular Genetics 2004;13(Spec No 1):R73-81. [MEDLINE: 14722155]
68. Sun K, Yang K, Challis JR. Glucocorticoid actions and metabolism in pregnancy: implications for placental function and fetal cardiovascular activity. Placenta 1998;19(5-6):353-60. [MEDLINE: 9699955]
69. Taro Pharmaceuticals. Diflorasone diacetate cream prescribing information. Pharmaceutical Information 1999.
70. ® Evaluations. ThomsonMicromedex 2009; Vol. 140.
71. Turpeinen M, Mashkilleyson N, Bjorksten F, Salo OP. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Dermato-Venereologica 1988;68(4):331-5. [MEDLINE: 2459879]
72. Turpeinen M. Adrenocortical response to adrenocorticotropic hormone in relation to duration of topical therapy and percutaneous absorption of hydrocortisone in children with dermatitis. European Journal of Pediatrics 1989;148(8):729-31. [MEDLINE: 2792121]
73. Uno H, Eisele S, Sakai A, Shelton S, Baker E, DeJesus O, et al. Neurotoxicity of glucocorticoids in the primate brain. Hormones & Behavior 1994;28(4):336-48. [MEDLINE: 7729802]
74. Walker BE. Induction of cleft palate in rabbits by several glucocorticoids. Proceedings of the Society for Experimental Biology & Medicine 1967;125(4):1281-4. [MEDLINE: 6042444]
75. Weatherhead S, Robson SC, Reynolds NJ. Eczema in pregnancy. BMJ (Clinical research ed.) 2007;335(7611):152-4. [PUBMED: 17641349]
76. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed 23 November 2006).
77. Wong FK, Hagg U. An update on the aetiology of orofacial clefts. Hong Kong Medical Journal 2004;10(5):331-6. [MEDLINE: 15479962]
78. Yamada H, Nakano M, Ichihashi T. Fetal concentration after topical application of betamethasone 17, 21-dipropionate (S-3440) ointment and teratogenesis in mice and rabbits. Pharmacometrics 1981;21(4):645-55.
79. Zip C. A practical guide to dermatological drug use in pregnancy. Skin Therapy Letter 2006;11(4):1-4. [MEDLINE: 16732394]
80. Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007346.pub2]